Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group plans to amend its existing articles of association and adopt a new set of articles to align with recent changes to Hong Kong’s Companies Ordinance and the Stock Exchange’s Listing Rules. The revisions are designed to support the treasury share regime, promote paperless corporate communications and introduce implied consent for website-based communications.
The proposed new articles will also facilitate hybrid and virtual general meetings, enable electronic voting and allow electronic submission of proxy instructions, reflecting current market practice and improving operational efficiency in corporate governance. Shareholders will vote on the special resolution to adopt the new articles at the company’s annual general meeting scheduled for 28 May 2026, with further details to be provided in a forthcoming circular.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company listed on the Hong Kong Stock Exchange. It operates in the healthcare and life sciences industry, focusing on the development, manufacture and sale of pharmaceutical products for domestic and international markets.
YTD Price Performance: 11.98%
Average Trading Volume: 105,362,476
Technical Sentiment Signal: Buy
Current Market Cap: HK$108.6B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.